Spondylitis News and Research

RSS

Johnson & Johnson' first-quarter 2010 sales increase 4.0% to $15.6 billion

Johnson & Johnson today announced sales of $15.6 billion for the first quarter of 2010, an increase of 4.0% as compared to the first quarter of 2009. Operational results declined 0.1% and the positive impact of currency was 4.1%.

21 Apr 2010

Axis Surgical's EC-MOR facilitated real-time visualization of anterior spine column during surgery

Axis Surgical Technologies, Inc., reports the first evaluation of the C-MOR™ Visualization Device in a spine procedure. The C-MOR™ is a self-contained portable direct-imaging tool that functions much like a standard arthroscopic tower, yet at a fraction of both the size and cost. The handheld lightweight device offers practitioners the convenience of intraoperative visualization and complete operability in one hand. The C-MOR™ comprises a distinctive and cost-effective imaging device offering benefits to medical practitioners in a variety of applications, including lengthy surgeries requiring constant re-evaluation of the operating field over the course of the surgery.

25 Mar 2010

Abbott declares quarterly dividend of 40 cents per share

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2009.

27 Jan 2010

New breakthroughs in AS genome-wide association study

Work done in part by researchers at The University of Texas Health Science Center at Houston has led to the discovery of two new genes that are implicated in ankylosing spondylitis (AS), an inflammatory and potentially disabling disease. In addition, the international research team pinpointed two areas along stretches of DNA that play an important role in regulating gene activity associated with the arthritic condition.

10 Jan 2010

Scientists and clinicians address diagnosis and treatment for autoimmune and autoinflammatory diseases

Autoimmune and autoinflammatory diseases are a major health issue. The National Institutes of Health reports that up to 23.5 million Americans are afflicted. The American Autoimmune Related Diseases Association reports the number is closer to 50 million. Scientists and clinicians at The University of Texas Health Science Center at Houston can address the diagnosis and treatment of these conditions, as well as the latest advances in research.

8 Jan 2010

Study reveals genomic switches separate autoimmune disorders in different clusters

Genomic switches can predispose an individual to one set of autoimmune disorders but protect the same person against another set of them, scientists at Stanford University School of Medicine have found.

24 Dec 2009

Emisphere's oral salmon calcitonin product addresses persistent musculoskeletal pain

Emisphere Technologies, Inc. today announced a meta-analysis published in the December 2009 edition of Rheumatology Reports examining independent evidence of the analgesic action of the hormone calcitonin. This publication restates the potential of calcitonin in filling a significant unmet need for alternative treatments for persistent musculoskeletal pain.

22 Dec 2009

Schering-Plough announces 2009 third quarter financial results

Schering-Plough Corporation (NYSE: SGP) today reported financial results for the 2009 third quarter.

22 Oct 2009

AstraZeneca and POZEN announce the pivotal data from two POZEN clinical trials

AstraZeneca and POZEN Inc. today announced pivotal data from two POZEN clinical trials that were presented at the American College of Rheumatology (ACR) 2009 Annual Scientific Meeting in Philadelphia, PA.

20 Oct 2009

Johnson & Johnson announces financial results for the third quarter of 2009

Johnson & Johnson today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%.

13 Oct 2009

Therapeutic principles of monoclonal antibodies

Professor Joachim R. Kalden, Member of the Department for Molecular Immunology, Nikolaus-Fiebiger-Zentrum, University Medical School Erlangen-Nuremberg, presents therapeutic principles based on monoclonal antibodies.

10 Sep 2009

New Drug Application for VIMOVO accepted by U.S. Food and Drug Administration

POZEN Inc. (NASDAQ:POZN), today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for VIMOVO™ (enteric-coated naproxen / immediate release esomeprazole magnesium, formerly know as PN 400).

31 Aug 2009

Array Biopharma reports Q4 and full year 2009 financials

Array reported revenue of $5.5 million for the fourth quarter of fiscal 2009, compared to revenue of $6.1 million for the same period in fiscal 2008. Array invested $21.3 million in proprietary research and development for the quarter to advance its seven wholly-owned drugs in clinical development and select discovery programs.

10 Aug 2009

Health Canada approves Simponi (golimumab) for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Centocor Ortho Biotech Inc. and Schering-Plough Corporation has announced that Health Canada has granted approval of Simponi (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS).

13 Apr 2009

FDA forces manufacturers of TNF-blockers to highlight risk of fungal infections

The U.S. Food and Drug Administration today announced that the manufacturers of Humira, Cimzia, Enbrel, and Remicade must strengthen the existing warnings, in the Warnings and Precaution sections of the drugs' prescribing information and Medication Guides, on the risk of developing opportunistic fungal infections. Some patients with invasive fungal infections have died.

5 Sep 2008

Could arthritis wonder drugs provide clues for all disease?

Drugs that have helped treat millions of rheumatoid arthritis sufferers may hold the key to many more medical conditions, including atherosclerosis - a leading cause of heart disease - says the researcher who jointly invented and developed them.

From The University of Manchester 17 Jul 2008

Evidence for an increased cancer risk following the use of radioactive Radium-224 in the therapy for Ankylosing Spondylitis

In the course of an epidemiological study, scientists of the Institute of Radiation Biology of the Helmholtz Zentrum München - German Research Center for Environmental Health - have established an unfavourable benefit-risk-ratio for ankylosing spondylitis patients treated with Radium-224 therapy (Rheumatology 2008; 47: 855-59).

23 Jun 2008